Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A.
J Comp Eff Res
; 11(10): 717-728, 2022 07.
Article
em En
| MEDLINE
| ID: mdl-35535702
ABSTRACT
Aim:
To determine if emicizumab was channeled to clinically complex people with hemophilia A upon approval.Methods:
Claims data (16 November 2017, through 31 December 2019) from US-based insurance databases were analyzed to compare the clinical complexity of people with hemophilia A initiating emicizumab with matched individuals receiving factor VIII (FVIII) episodically or prophylactically. People with hemophilia A with evidence of previous bypassing agent use (indicating FVIII inhibitors) were excluded. Outcomes included bleeding events, arthropathy, pain, comorbidities and healthcare costs.Results:
A larger proportion of emicizumab users had bleeding events, comorbidities and arthropathy and greater healthcare costs in the year prior to starting emicizumab compared with FVIII users.Conclusion:
Claims-based data limitations prevent an absolute conclusion. Nevertheless, emicizumab users appear more clinically complex than FVIII users, suggesting post-approval channeling.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hemostáticos
/
Anticorpos Biespecíficos
/
Hemofilia A
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article